TY - JOUR
T1 - Endobronchial valves for severe emphysema
AU - Hartman, Jorine E.
AU - Vanfleteren, Lowie E. G. W.
AU - van Rikxoort, Eva M.
AU - Klooster, Karin
AU - Slebost, Dirk-Jan
N1 - Funding Information:
Support statement: All authors received a grant from the Dutch Lung foundation for the SOLVE trial (grant number: 5.1.17.171).
Funding Information:
Conflict of interest: J.E. Hartman has nothing to disclose. L.E.G.W. Vanfleteren reports personal fees from PulmonX, outside the submitted work. E.M. van Rikxoort reports other funding from Thirona, during the conduct of the study. K. Klooster has nothing to disclose. D-J. Slebos reports grants, personal fees, non-financial support and other funding from PulmonX Inc., CA, USA, during the conduct of the study; and grants, personal fees, non-financial support and other funding from PneumRx/BTG, CA, USA, outside the submitted work.
Publisher Copyright:
© ERS 2019.
PY - 2019/6/30
Y1 - 2019/6/30
N2 - The results of the randomised controlled trials investigating the bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) are promising, and have led to their inclusion in treatment guidelines, US Food and Drug Administration approval and inclusion in routine care in an increasing number of countries. The one-way valve treatment has advanced and is now a regular treatment option. However, this new phase will lead to new challenges in terms of implementation. We believe that key issues in future research concern advanced patient selection, improved methods for target lobe selection, increased knowledge on the predictive risk of a pneumothorax, positioning of pulmonary rehabilitation in conjunction with the EBV treatment, the positioning of lung volume reduction surgery versus EBV treatment, and the long-term efficacy, adverse events, impact on exacerbations and hospitalisations, costs and survival. Hopefully, the increasing number of patients treated, the setup of (inter) national registries and future research efforts will further optimise all aspects of this treatment.
AB - The results of the randomised controlled trials investigating the bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) are promising, and have led to their inclusion in treatment guidelines, US Food and Drug Administration approval and inclusion in routine care in an increasing number of countries. The one-way valve treatment has advanced and is now a regular treatment option. However, this new phase will lead to new challenges in terms of implementation. We believe that key issues in future research concern advanced patient selection, improved methods for target lobe selection, increased knowledge on the predictive risk of a pneumothorax, positioning of pulmonary rehabilitation in conjunction with the EBV treatment, the positioning of lung volume reduction surgery versus EBV treatment, and the long-term efficacy, adverse events, impact on exacerbations and hospitalisations, costs and survival. Hopefully, the increasing number of patients treated, the setup of (inter) national registries and future research efforts will further optimise all aspects of this treatment.
KW - LUNG-VOLUME-REDUCTION
KW - TERM-FOLLOW-UP
KW - THERAPY
KW - PNEUMOTHORAX
KW - SURVIVAL
KW - TRIAL
KW - PREDICTORS
U2 - 10.1183/16000617.0121-2018
DO - 10.1183/16000617.0121-2018
M3 - (Systematic) Review article
C2 - 30996040
SN - 0905-9180
VL - 28
SP - 1
EP - 7
JO - European Respiratory Review
JF - European Respiratory Review
IS - 152
M1 - 180121
ER -